Study details
Enrolling now
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Nationwide Children's Hospital
NCT IDNCT05503134ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
20
Study length
about 5 years
Ages
1–24
Locations
1 site in OH
About this study
This trial is testing the safety and effectiveness of a treatment using universal donor natural killer cells in people with relapsed or refractory acute myeloid leukemia (AML). The goal is to determine the best dose of this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Universal Donor Natural Killer Cells
PhasePhase 1/Phase 2
Primary goalIncidence and severity of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence and severity of adverse events
Secondary: CR rate after first cycle, Minimal Residual Disease (MRD) negative response rate by flow cytometry, Relapse free survival and overall survival
Body systems
Oncology